Yesterday, inspired by a post by fellow ScienceBlogger Martin, I had a little fun discussing the evolution of “alternative” medicine (a.k.a. “complementary and alternative medicine” or CAM), specifically speculating about the possible selective pressures, positive and negative, that have influenced the course that its evolution took. Essentially, the discussion centered around whether, by its very […]
Abel Pharmboy at Terra Sigillata has the full story. In brief, Medicare has slashed reimbursement for two radioimmunotherapy drugs Bexxar (131I-tositumomab) and Zevalin (90Y-ibritumomab) to below acquisition cost. This is not some experimental therapy that’s being denied, but rather a therapy with a established clinical efficacy. Naturally, this is likely to lead to most centers […]
Share this:
I wish I had thought of this one, but I didn’t. However, I never let a little thing like not having thought of an idea first to stop me from discussing it, and this particular idea is definitely worth expanding upon because (1) it’s interesting and (2) it combines two of my interests, alternative medicine […]
Share this:
Friday morning while doing some work in my office, I was treated to a discussion by the two hosts of a morning radio talk show. The talk was apparently prompted by a rather odd website, ihateyoungpeople.com, which asks: We want you to create a video of yourself explaining what you hate the most about young […]
Share this:
Hilarious. Even though I risk bringing back some of the anthropogenic global warming “skeptics” (in reality pseudoskeptics) here, this is too rich not to mention, because it reminds me of how advocates of all stripes of pseudoscience react, particularly advocates of alternative medicine, most of whom wouldn’t recognize a well-designed study if it bit them […]
